

SERUM EXCHANGE #560

Sera 1233-1236

The results for **Serum Exchange 560 (sera 1233 - 1236)**, are summarized in Tables 16 -21 and individual laboratory results by method are listed in

Tables 22-32. Sera strongly positive to A1, A10, A11, and A2 were examined in this study.

1233	method	#labs	A1	A25	A26	A34	A66	A6601	A36	A11	A1101	A1102	B8	A23	A24	A43	A80	B18	B35	B41	B42	B45	B50	B54	B55	B56	B59	B62	B64	B65	B67	B7	B71	B73	B75	B76	
class I	NIH-Std	3	67	33	33	33	33			67			67																								
	NIH-Ext	2	50	50	50	50	50			50																											
	AHG	3	100	100	100	100	100		100	100			100	67	67																						
	Luminex	27	100	100	100	100	74	41	100	89	30	30	100	100	96	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
	C1q	1	no consensus																																		
	Other	1	no consensus																																		
1233	method	#labs	Cw6	Cw7	Cw18	B60	B61	B72	B78	B38	B39	B3901	B48	B81	B8101	B51	B82	B37	B77	B53	B27	B2708	Bw6	A33	A3	A68	Cw4	Cw17	Cw15	Cw2	B52						
	Luminex	27	100	100	96	96	93	96	96	89	89	22	89	89	30	89	85	85	81	70	63	59	48	48	33	26	81	70	44	30	22						

1233	method	#labs	DQ2	DR7	DP19	DR16	DQ5	DR52	DQA1*01	DQA1*05	DQ6
class II	NIH-Ext	1	no specificities assigned								
	Luminex	25	100	68	60	24	24	10	12	12	8
	C1q	1	no consensus								
	Other	1	no specificities assigned								

Serum 1233 was reported as positive to A1 and A10 (A24, A26, A34) by all methods. Additional reactivity to A66, A11, and 1C specificities was reported by various methods. Strong reactivity to 5C, 7C, and 8C specificities, as well as anti-Cw6, -Cw7, -Cw18 reactivity, was reported by Luminex. In addition to the allele specific reactivity listed above,

some luminex labs also reported allele specific A*24;02 reactivity. For class II, strong anti-DQ2 reactivity was reported by Luminex and Flow PRA. Additional anti-DR7 and DP19 reactivity was also reported by a number of Luminex labs.

1234	method	#labs	A25	A26	A66	A6601	A6602	A11	A1101	A1102	A34	A1	A80	A68	A69	A28	A3	A2	A31	A33	A36	A43	A74	A30	A29	A24	A2403	A203
class I	NIH-Std	3	33	33	33			67			33																	
	NIH-Ext	2	100	100	100			100			100	50					50											
	AHG	3	67	100	100			100			67	33	33	33		33												
	Luminex	27	100	100	41	37	37	85	30	30	100	100	100	100	100		100	100	100	100	100	100	100	100	93	37	37	33
	C1q	1	no consensus																									
	Other	1	no consensus																									

1234	method	#labs	DQ7	DQ8	DQ9	DR1	DR10	DR4	DQ4	DR14	DR15	DR51	DQA1*03	DQ2	DR13	DP14	DQA1*06	DQA1*04	DQA1*05	DR1404	DPW5	DQ3	DQ6	DR103	DR16	DR17	DR18	DR8
class II	NIH-Ext	1	no specificities assigned																									
	Luminex	25	100	100	100	100	100	100	100	100	100	84	64	28	20	16	16	12	12	12	8	8	8	8	8	8	8	8
	C1q	1	no consensus																									
	Other	1	no consensus																									

For **Serum 1234**, anti-A25 and –A26 reactivity was reported by all methods. Additional reactivity to A66, A34, A28 (A68, A69), as well as reactivity to a number of 1C specificities, was reported by various methods. Additional reactivity to A33 and A74 was also reported by Luminex. Allele level reactivity to A*24:03 was reported by 2 Luminex labs. For class II, reactivity to DR4,

DQ4, DQ7, DQ8, and DQ9 was reported by Luminex, Flow PRA, and C1q. Additional reactivity to DR1, DR10, and DR15, was reported by Luminex and Flow PRA. Anti-DR14 and ant-DR51 reactivity was also reported by Luminex.

1235	method	#labs	A2	B57	B58	A68	A69	A28	B18	B64	B65	B27	B2708	B45	B44	B50	B51	B54	B55	B67	B72	B76	B35	B62	B47	B49	B53	
class I	NIH-Std	3	33																									
	NIH-Ext	2	100	100	100																							
	AHG	3	100	67	67	67		33	33	33	33	33																
	Luminex	27	100	100	100	100	100		100	100	100	96	44	96	93	96	96	96	96	96	96	96	96	96	96	96	96	96
	C1q	1	no consensus																									
	Other	1	no consensus																									
1235	method	#labs	B56	B71	B63	B13	B38	B39	B3901	B52	B75	B77	B78	B7801	B59	B46	B37	B82	A24	A2403	Cw5	B73	A33	A23	Bw4	A203		
	Luminex	27	96	96	96	93	93	91	26	93	93	93	93	22	93	89	89	81	67	19	59	56	56	48	33	30		

1235	method	#labs	DR11	DR13	DR14	DR17	DR18	DPw2	DPw3	DPw6	DR52	DR7	DQ2	DP18	DP28	DP14	DP17	DP9	DP10	DP20	DP402	DPw4	DQA1*05	DR1403	DPA1*01	DPA1*04	DR16	DR3	DQ7
class II	NIH-Ext	1	no specificities assigned																										
	Luminex	25	100	100	100	100	100	96	96	96	96	96	96	92	92	88	88	84	80	80	60	60	20	16	12	12	12	12	8
	C1q	1	no consensus																										
	Other	1	no consensus																										

Serum 1235 was reported as positive to A2 by all methods. In addition, anti-B57 and -B58 reactivity was reported by all methods, except NIH-standard and C1q. Luminex and antiglobulin also reported reactivity to B18, B64, B65, and B27, with some labs reporting allele specific B*27:08 reactivity. Additional reactivity to B38, B39, B44, B45, B50, as well as reactivity to 5C

and 7C specificities, was reported by Luminex. For class II, Luminex, Flow PRA, and C1q each reported reactivity to DR11, DR17, DR18, and DR52. Additional reactivity to DQ2, DR13 and DR14 was reported by Luminex and Flow PRA. In addition, reactivity to a number of DP specificities was also reported by Luminex and C1q.

1236	method	#labs	A2	B57	B58	A68	A69	A28	B62	B35	B46	B50	B13	B51	B45	B52	B53	B56	B61	B71	B72	B70	B44	B55	B49	B63	B75	B76	B77	Cw6	Cw2	Cw15	Cw17	Cw18	Cw4	Cw5	A74	A24	A2403	
class I	NIH-Std	3	67																																					
	NIH-Ext	2	100	50																																				
	AHG	3	10	100	33	100		67	67	33	33	33	33	33	33	33	33	33	33		33	33	33	33																
	Luminex	27	100	100	100	100	100		100	100	100	100	96	93	89	100	100	100	26	100	100		93	96	100	100	100	100	100	100	100	96	96	96	96	96	96	93	93	33
	C1q	1	no consensus																																					
	Other	1	no consensus																																					
1236	method	#labs	A3	A32	A29	A11	A1101	A1102	Cw12	A31	A23	B78	B7801	B27	B2708	B67	A34	B38	Cw10	A30	B54	Cw9	A25	B64	A33	A43	B41	B42	B59	B39	A66	A6602	B18	B37	B48	A203	A26	B47	B65	B7
	Luminex	27	89	89	85	81	30	26	78	74	70	85	22	70	30	70	67	59	59	56	56	56	52	52	52	48	44	44	44	41	41	22	33	33	33	30	30	26	26	22

1236	method	#labs	DQ4	DQ8	DQ9	DR1	DR4	DR9	DQ6	DR53	DQ5	DR7	DQA1*03	DR14	DR10	DQ2	DR51	DR15	DQ7	DQA1*01	DP23	DQ3
class II	NIH-Ext	1	no specificities assigned																			
	Luminex	25	100	100	100	100	100	100	96	96	96	92	60	60	40	28	28	0	20	16	8	8
	C1q	1	no consensus																			
	Other	1	no consensus																			

For **Serum 1236**, A2 reactivity was reported by all methods. Additional reactivity B57 and B58 was also reported by various methods. In addition, Luminex and antiglobulin reported reactivity to a number of 5C and 7C specificities. Luminex labs also reported C-locus reactivity to Cw2, Cw4, Cw5, Cw15, Cw17, and Cw18, as well as anti-A24 and -A74 reac-

tivity. Strong class II reactivity to DR4 was reported by Luminex, Flow PRA, and C1q. In addition, reactivity to DQ4, DQ5, DQ6, DQ8, DQ9, DR1, and DR9 was reported by Luminex and Flow PRA. Strong anti-DR7 and DR53 was also reported by Luminex.

NEXT MAILING DATE: March 7, 2018

Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed

Table 16. Summary of the 560th Serum Exchange (Serum #1233-1236) by NIH-Standard and NIH-Extended - class I

Method: NIH-Standard											
*** Serum 1233 ***			*** Serum 1234 ***			*** Serum 1235 ***			*** Serum 1236 ***		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A1	67%	100%	A11	67%	100%	A2	33%	100%	A2	67%	92%
B8	67%	100%	A25	33%	100%						
A11	67%	50%	A26	33%	100%						
A25	33%	100%	A34	33%	100%						
A26	33%	100%	A66	33%	100%						
A34	33%	100%									
A66	33%	100%									

Method: NIH-Extended											
*** Serum 1233 ***			*** Serum 1234 ***			*** Serum 1235 ***			*** Serum 1236 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A1	50%	100%	A11	100%	100%	B57	100%	100%	A2	100%	100%
A11	50%	100%	A26	100%	100%	B58	100%	100%	B57	50%	100%
A25	50%	100%	A66	100%	100%	A2	100%	94%			
A26	50%	100%	A25	100%	67%						
A34	50%	100%	A34	100%	50%						
A66	50%	100%	A1	50%	73%						
			A3	50%	50%						

Table 17. Summary of the 560th Serum Exchange (Serum #1233-1236) by Antiglobulin - class I

Method: Antiglobulin											
*** Serum 1233 ***			*** Serum 1234 ***			*** Serum 1235 ***			*** Serum 1236 ***		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A1	100%	100%	A11	100%	100%	A2	100%	100%	A2	100%	100%
A11	100%	100%	A26	100%	100%	A68	67%	100%	A68	100%	100%
A25	100%	100%	A66	100%	100%	B58	67%	100%	B57	100%	100%
A26	100%	100%	A25	67%	100%	B57	67%	75%	A28	67%	100%
A34	100%	100%	A34	67%	100%	A28	33%	100%	B62	67%	100%
A36	100%	100%	A1	33%	100%	B65	33%	100%	B13	33%	100%
A66	100%	100%	A80	33%	100%	B64	33%	67%	B35	33%	100%
B8	100%	100%	A68	33%	62%	B18	33%	50%	B45	33%	100%
A23	67%	100%	A28	33%	33%	B27	33%	50%	B46	33%	100%
A24	67%	100%							B50	33%	100%
A32	33%	100%							B51	33%	100%
A80	33%	100%							B52	33%	100%
B64	33%	100%							B56	33%	100%
B65	33%	100%							B58	33%	100%
BW6	33%	100%							B61	33%	100%
									B70	33%	100%
									B72	33%	100%
									B53	33%	83%
									B55	33%	83%
									B44	33%	78%

Table 18. Summary of the 560th Serum Exchange (Serum #1233-1236) by Other and C1q - class I

Method: Other											
*** Serum 1233 ***			*** Serum 1234 ***			*** Serum 1235 ***			*** Serum 1236 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: C1q											
*** Serum 1233 ***			*** Serum 1234 ***			*** Serum 1235 ***			*** Serum 1236 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Table 19. Summary of the 560th Serum Exchange (Serum #1233-1236) by Luminex - class I

Method: Luminex - Cont.								
*** Serum 1233 ***			*** Serum 1235 ***			*** Serum 1236 ***		
27 typing Labs			27 typing Labs			27 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B61	93%	100%	B39	81%	100%	A29	85%	100%
A11	89%	100%	B82	81%	100%	B78	85%	100%
B38	89%	100%	A24	67%	100%	A11	81%	92%
B39	89%	100%	Cw5	59%	100%	Cw12	78%	100%
B48	89%	100%	B73	56%	100%	A31	74%	100%
B81	89%	100%	A33	56%	50%	A23	70%	100%
B51	89%	86%	A23	48%	100%	B27	70%	100%
B82	85%	100%	B2708	44%	100%	B67	70%	100%
B37	85%	75%	Bw4	33%	77%	A34	67%	75%
B77	81%	100%	A203	30%	100%	B38	59%	100%
Cw4	81%	100%	B3901	26%	100%	Cw10	59%	100%
A66	74%	88%	B7801	22%	100%	A30	56%	100%
B53	70%	100%	A2403	19%	100%	B54	56%	100%
Cw17	70%	100%				Cw9	56%	100%
B27	63%	71%				A25	52%	100%
B2708	59%	100%				B64	52%	100%
A33	48%	100%				A33	52%	75%
Bw6	48%	100%				A43	48%	100%
Cw15	44%	100%				B41	44%	100%
A6601	41%	100%				B42	44%	100%
A3	33%	100%				B59	44%	100%
A1101	30%	100%				B39	41%	100%
A1102	30%	100%				A66	41%	75%
B8101	30%	100%				A2403	33%	100%
Cw2	30%	100%				B18	33%	100%
A68	26%	100%				B37	33%	100%
B3901	22%	100%				B48	33%	100%
B52	22%	100%				A1101	30%	100%
B46	19%	100%				A203	30%	100%
B8201	19%	100%				A26	30%	100%
						B2708	30%	100%
						A1102	26%	100%
						B47	26%	100%
						B65	26%	100%
						B61	26%	50%
						A6602	22%	100%
						B7	22%	100%
						B7801	22%	100%

Table 20. Summary of the 560th Serum Exchange (Serum #1233-1236) by - NIH-Extended, Other and C1q class II

Method: NIH-Extended															
*** Serum 1233 ***				*** Serum 1234 ***				*** Serum 1235 ***				*** Serum 1236 ***			
1 typing Lab				1 typing Lab				1 typing Lab				1 typing Lab			
Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion	
no specificities assigned				no specificities assigned				no specificities assigned				no specificities assigned			

Method: Other															
*** Serum 1233 ***				*** Serum 1234 ***				*** Serum 1235 ***				*** Serum 1236 ***			
1 typing Lab				1 typing Lab				1 typing Lab				1 typing Lab			
Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion	
no consensus				no consensus				no consensus				no consensus			

Method: C1q															
*** Serum 1233 ***				*** Serum 1234 ***				*** Serum 1235 ***				*** Serum 1236 ***			
1 typing Lab				1 typing Lab				1 typing Lab				1 typing Lab			
Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion	
no specificities assigned				no consensus				no consensus				no consensus			

Table 21. Summary of the 560th Serum Exchange (Serum #1233-1236) by - Luminex class II

Method: Luminex											
*** Serum 1233 ***			*** Serum 1234 ***			*** Serum 1235 ***			*** Serum 1236 ***		
25 typing Labs			25 typing Labs			25 typing Labs			25 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DQ2	100%	90%	DQ7	100%	100%	DR11	100%	100%	DQ4	100%	100%
DR7	68%	100%	DQ8	100%	100%	DR13	100%	100%	DQ8	100%	100%
DP19	60%	100%	DQ9	100%	100%	DR14	100%	100%	DQ9	100%	100%
DR16	24%	100%	DR1	100%	100%	DR17	100%	100%	DR1	100%	100%
DQ5	24%	50%	DR10	100%	100%	DR18	100%	100%	DR4	100%	100%
DR52	20%	33%	DR4	100%	100%	DPw2	96%	100%	DR9	100%	89%
DQA1*01	12%	100%	DQ4	100%	93%	DPw3	96%	100%	DQ6	96%	100%
DQA1*05	12%	100%	DR14	100%	70%	DPw6	96%	100%	DR53	96%	95%
DQ6	8%	100%	DR15	100%	64%	DR52	96%	100%	DQ5	96%	91%
DP13	4%	100%	DR51	84%	55%	DR7	96%	100%	DR7	92%	100%
DQA1*02	4%	100%	DQA1*03	64%	100%	DQ2	96%	95%	DQA1*03	60%	100%
DQA1*04	4%	100%	DQ2	28%	20%	DP18	92%	100%	DR14	60%	33%
DR18	4%	100%	DR13	20%	100%	DP28	92%	100%	DR10	40%	100%
DR9	4%	100%	DP14	16%	100%	DP14	88%	100%	DQ2	28%	55%
			DQA1*06	16%	100%	DP17	88%	100%	DR51	28%	50%
			DQA1*04	12%	100%	DP9	84%	100%	DR15	20%	100%
			DQA1*05	12%	100%	DP10	80%	100%	DQ7	20%	20%
			DR1404	12%	100%	DP20	80%	100%	DQA1*01	16%	100%
			DPw5	8%	100%	DP402	60%	92%	DP23	8%	100%
			DQ3	8%	100%	DPw4	60%	50%	DQ3	8%	100%
			DQ6	8%	100%	DQA1*05	20%	100%	DP13	4%	100%
			DR103	8%	100%	DR1403	16%	100%	DQA1*04	4%	100%
			DR16	8%	100%	DPA1*01	12%	100%			
			DR17	8%	100%	DPA1*04	12%	100%			
			DR18	8%	100%	DR16	12%	100%			
			DR8	8%	100%	DR3	12%	100%			
			DP10	4%	100%	DQ7	8%	20%			
			DPw1	4%	100%	DR15	4%	100%			
			DPw4	4%	100%	DR5	4%	100%			
			DQ1	4%	100%	DR6	4%	100%			
			DQ5	4%	100%						
			DQA1*02	4%	100%						
			DR2	4%	100%						
			DR53	4%	100%						
			DR6	4%	100%						

Table 22. Individual laboratory results for Serum #1233-1236 by NIH-Standard and NIH-Extended - class I

Investigator	**** Serum 1233 ****											**** Serum 1234****						**** Serum 1235 ****				**** Serum 1236 ****				Method
	Ctr	% POS	A1	B8	A11	A25	A26	A34	A66	Other	% POS	A11	A25	A26	A34	A66	Other	% POS	A2	Other	% POS	A2	Other			
Fort, Marylise	4079	NT									NT						NT				NT			STD		
Hogan, Patrick	3808	49	+	+	+						11	+					4				47	+		STD		
McCluskey, James	3582	56									28						69				66			STD		
Vasilescu, Rodica	786	25	+	+	+	+	+	+	+		33	+	+	+	+	+	17	+			17	+		STD		

Investigator	**** Serum 1233 ****											**** Serum 1234****						**** Serum 1235 ****				**** Serum 1236 ****				Method
	Ctr	% POS	A1	A11	A25	A26	A34	A66	Other	% POS	A11	A26	A66	A25	A34	Other	% POS	B57	B58	A2	Other	% POS	A2	B57	Other	
Lardy, N.M.	725	78	+	+	+	+	+	+		54	+	+	+	+	+	A1,A3	44	+	+	+	48	+	+		EXT	
Reed, Elaine F. PhD	3753	77								39	+	+	+	+	+		42	+	+	+	45	+			EXT	

Table 23. Individual laboratory results for Serum #1233-1236 by Antiglobulin

Investigator	**** Serum 1233 ****													**** Serum 1234 ****						Method		
	Ctr	% POS	A1	A11	A25	A26	A34	A36	A66	B8	A23	A24	Other	Ctr	% POS	A11	A26	A66	A25		A34	Other
Cecka, J. Michael F	774	100	+	+	+	+	+	+	+	+	+	+	A80,BW6	774	68	+	+	+	+	+	A1,A28,A68,A80	Antiglobulin
Hahn, Amy B. PhD	910		+	+	+	+	+	+	+				A32,B64,B65	910		+	+	+				Antiglobulin
Vasilescu, Rodica	786	43	+	+	+	+	+	+	+	+	+	+		786	21	+	+	+	+	+		Antiglobulin

Investigator	**** Serum 1235 ****											**** Serum 1236 ****						Method			
	Ctr	% POS	A2	A68	B58	B57						Other	Ctr	% POS	A2	A68	B57		A28	B62	Other
Cecka, J. Michael F	774	57	+	+	+	+						B27,A28,B64,B	774	82	+	+	+	+	+	B61,B70,B50,B13	Antiglobulin
Hahn, Amy B. PhD	910		+		+	+							910		+	+	+	+	+	B46	Antiglobulin
Vasilescu, Rodica	786	29	+	+									786	36	+	+	+				Antiglobulin

Table 24. Individual laboratory results for Serum #1233-1236 by Other and C1q - class I

Investigator	Ctr	**** Serum 1233 ****											**** Serum 1234 ****					**** Serum 1235 ****					**** Serum 1236 ****					Method						
		% POS	A1	A11	A23	A24	A25	A26	A34	A36	A80	B8	Other	% POS	A1	A11	A25	A26	Other	% POS	A2	A68	B18	B57	B58	Other	% POS		A2	A68	B35	B49	B50	Other
Reed, Elaine F. F	3753	86	+	+	+	+	+	+	+	+	+	+		94	+	+	+	+	A34,A36	78	+	+	+	+	+	B57,B58	66	+	+	+	+	+	B57,B58,B62+	Other

Other = Flow PRA

Investigator	Ctr	**** Serum 1233 ****											**** Serum 1234 ****					**** Serum 1235 ****					**** Serum 1236 ****					Method						
		% POS	A1	A11	A23	A24	A25	A26	A34	A36	A80	B8	Other	% POS	A11	A26	A43	A6601	Other	% POS	A2					Other	% POS		A2	A68	A69			Other
Colombe, Beth W	3632	22	+	+	+	+	+	+	+	+	+	+	A43,A6601,B73+	7	+	+	+	+		5	+						6	+	+	+				C1q

Table 25. Individual laboratory results for Serum #1233 by Luminex - class I, cont.

		**** Serum 1233 ****																							
Investigator	Ctr	Cw4	A66	B53	Cw17	B27	B2708	A33	Bw6	Cw15	A6601	A3	A1101	A1102	B8101	Cw2	A68	B3901	B52	B46	B8201	B703	B7801	Other	
Al-Attas, Rabab A. M	8062	+	+	+	+	+			+	+															A*24:02
Arnold, Paula PhD	5462	+	+			+	+				+		+	+	+			+				+		+	A*68:01,A*66:02,A*24:02
Bengochea, Carrette	8045		+				+											+					+		
Cecka, J. Michael P	774		+			+			+																
Chen, Dong-Feng P	3224	+		+	+		+			+	+		+	+	+							+			
Colombe, Beth w. P	3632	+		+	+		+		+																A6602
Daniel, Dolly	5219		+				+		+				+	+	+			+					+		A9,B15,B70,A10 >
Du, Keming	8086	+	+		+	+																			
Dunckley, Heather	3766	+	+	+	+	+	+	+		+	+		+	+	+			+					+		+
Fort, Marylise	4079	+	+	+	+	+		+		+		+				+	+		+	+					A32,Cw9,Cw8,Cw14 >
Gebel, Howard PhD	5214	+		+			+	+	+		+														
Hahn, Amy B. PhD	910	+	+	+	+	+		+	+																
Hamdi, Nuha	810	+	+	+	+	+		+		+		+				+	+		+						Cw8,Cw14
Hogan, Patrick	3808	+	+	+		+			+		+		+	+	+									+	
Holdsworth, Rhonda	615	+	+	+	+	+	+	+		+	+	+				+									
Lardy, N.M.	725		+				+																		
Mayne, Elizabeth	8103		+	+		+	+		+		+		+	+	+			+					+	+	B40,B15,B14
McCluskey, James	3582	+		+	+		+	+		+	+	+				+	+		+	+					A6602,A*68:02
Pancoska, Carol Ph	54	+	+	+	+		+	+																	
Permpikul, Vejbaesy	3966	+	+		+	+																			
Pule, Ziningi	8058	+	+	+	+	+		+	+	+		+						+							Bw4
Reed, Elaine F. PhD	3753	+		+	+		+		+		+														A*24:02
Sacchi, Nicoletta	8100	+	+	+	+	+		+	+		+					+									
V.Brouard, M.Tonye	8048	+		+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			B40,Cw9,A2403
Vasilescu, Rodica	786	+			+		+				+		+	+	+							+		+	
Vather/JHB,	4322	+	+	+	+	+	+	+	+	+		+				+	+		+	+					
Vather/Pinetown,	8082	+	+	+	+	+	+	+	+	+		+				+	+		+	+					B44,Cw8,Cw14,Cw12

Table 28. Individual laboratory results for Serum #1236 by Luminex - class I, cont.

		**** Serum 1236 ****																																	
Investigator	Ctr	Cw10	A30	B54	Cw9	A25	B64	A33	A43	B41	B42	B59	B39	A66	A2403	B18	B37	B48	A1101	A203	A26	B2708	A1102	B47	B65	B61	A6602	B7	B7801	B81	Bw4	Cw403	Other	Method	
Al-Attas, Rabab A. M	8062	+		+	+		+						+	+																					LMX
Arnold, Paula PhD	5462														+				+	+			+												LMX
Bengochea, Carrette	8045														+					+															LMX
Cecka, J. Michael P	774																																		LMX
Chen, Dong-Feng P	3224	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+	+		+	+				+		+						LMX
Colombe, Beth w. P	3632	+			+																											+			LMX
Daniel, Dolly	5219														+				+	+		+										+	A9,B15,B70,B21	LMX	
Du, Keming	8086	+	+	+	+	+	+	+	+					+																					LMX
Dunckley, Heather	3766	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+		A6601,B3901	LMX	
Fort, Marylise	4079	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+			+				+	+									LMX
Gebel, Howard PhD	5214		+	+		+	+	+	+	+	+	+	+	+		+	+					+					+						A6601	LMX	
Hahn, Amy B. PhD	910		+																																LMX
Hamdi, Nuha	810	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+			+			+	+	+									LMX
Hogan, Patrick	3808														+				+	+		+	+									+			LMX
Holdsworth, Rhonda	615	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+			+			+	+	+		+		+					LMX
Lardy, N.M.	725																															+			LMX
Mayne, Elizabeth	8103														+				+	+			+						+			+	B15	LMX	
McCluskey, James	3582	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+			+			+	+	+		+		+			B60,B82,A36	LMX	
Pancoska, Carol Ph	54	+	+	+	+	+	+	+	+					+								+													LMX
Permpikul, Vejbaes	3966																																		LMX
Pule, Ziningi	8058	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+			+			+	+	+		+		+	+		B60,B82,A36,B73	LMX	
Reed, Elaine F. PhD	3753																																		LMX
Sacchi, Nicoletta	8100	+																																	LMX
V.Brouard, M.Tonye	8048	+	+	+	+	+		+	+	+	+	+			+	+	+	+	+	+	+	+	+	+		+				+		B14,Bw6,A6601,B	LMX		
Vasilescu, Rodica	786	+	+	+	+	+	+	+	+	+	+	+			+				+	+		+	+			+		+				B3901		LMX	
Vather/JHB,	4322	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+			+			+	+	+		+		+	+				LMX
Vather/Pinetown,	8082	+	+	+	+	+	+	+		+	+	+	+	+				+	+								+	+							LMX

Table 30. Individual laboratory results for Serum #1233-1234 by Luminex - class II

Investigator	**** Serum 1233 ****									**** Serum 1234 ****														Method				
	Ctr	% POS	DQ2	DR7	DP19	DR16	DQ5	DR52	Other	% POS	DQ7	DQ8	DQ9	DR1	DR10	DR4	DQ4	DR14	DR15	DR51	DQA1*03	DQ2	DR13		DP14	DQA1*06	Other	
Al-Attas, Rabab A. M	8062		+	+				+	DR9		+	+	+	+	+	+	+	+	+	+	+							LMX
Arnold, Paula PhD	5462		+		+						+	+	+	+	+	+	+	+	+	+	+						DRB5*02:02	LMX
Bengochea, Carrette	8045	6	+	+						39	+	+	+	+	+	+	+	+	+	+	+	+					DR1404,DQ1,DPW4	LMX
Cecka, J. Michael P	774	23	+							74	+	+	+	+	+	+	+	+	+	+	+							LMX
Chen, Dong-Feng P	3224		+	+	+						+	+	+	+	+	+	+	+	+	+	+							LMX
Colombe, Beth W. F	3632	37	+		+					82	+	+	+	+	+	+	+	+	+	+	+							LMX
Daniel, Dolly	5219	5	+							31	+	+	+	+	+	+	+	+	+	+	+		+			DR2,DR6,DR1404,DQ3	LMX	
Du, Keming	8086	7	+	+	+					29	+	+	+	+	+	+	+	+	+	+	+		+					LMX
Dunckley, Heather	3766	66	+	+				+	DR18	89	+	+	+	+	+	+	+	+	+	+	+							LMX
Fort, Marylise	4079		+	+	+	+	+	+	DQ6,DP13		+	+	+	+	+	+	+	+	+	+		+		+				LMX
Gebel, Howard PhD	5214	32	+		+				DQA1*01:01	97	+	+	+	+	+	+	+	+	+	+	+							LMX
Hahn, Amy B. PhD	910		+	+							+	+	+	+	+	+	+	+	+	+		+						LMX
Hamdi, Nuha	810	31	+	+			+	+		71	+	+	+	+	+	+	+	+	+	+		+						LMX
Hogan, Patrick	3808		+	+							+	+	+	+	+	+	+	+	+	+								LMX
Holdsworth, Rhonda	615		+	+	+	+	+				+	+	+	+	+	+	+	+	+	+	+		+	+		DRB5*02:02	LMX	
Mayne, Elizabeth	8103	5	+							33	+	+	+	+	+	+	+	+	+	+	+				+	DR1404,DQ3,DQA1*04	LMX	
McCluskey, James	3582		+	+	+						+	+	+	+	+	+	+	+	+	+		+				DQA1*03:01	LMX	
Pancoska, Carol Ph	54		+	+	+						+	+	+	+	+	+	+	+	+	+								LMX
Permpikul, Vejbaesy	3966	6	+		+				DQA1*05	33	+	+	+	+	+	+	+	+	+	+	+				+	DQA1*05	LMX	
Pule, Ziningi	8058	8	+	+			+			35	+	+	+	+	+	+	+	+	+	+		+	+					LMX
Reed, Elaine F. PhD	3753		+		+						+	+	+	+	+	+	+	+	+	+						DRB5*02:02	LMX	
Sacchi, Nicoletta	8100		+	+	+	+	+		DQ6		+	+	+	+	+	+	+	+	+	+		+						LMX
V.Brouard, M.Tonye	8048	31	+	+	+	+			DQA1*01,DQA1*02	80	+	+	+	+	+	+	+	+	+	+	+							LMX
Vather/JHB,	4322		+	+	+	+			DQA1*01,DQA1*04,DQA1*05		+	+	+	+	+	+	+	+	+	+	+		+	+		DR103,DR8,DR16,DR17 >	LMX	
Vather/Pinetown,	8082		+	+	+	+	+	+	DQA1*01,DQA1*05		+	+	+	+	+	+	+	+	+	+	+		+	+	+	DR103,DR8,DR9,DR16 >	LMX	

Table 31. Individual laboratory results for Serum #1235 by Luminex - class II

		**** Serum 1235 ****																									
Investigator	Ctr	% POS	DR11	DR13	DR14	DR17	DR18	DPw2	DPw3	DPw6	DR52	DR7	DQ2	DP18	DP28	DP14	DP17	DP9	DP10	DP20	DP402	DPw4	DQA1*05	DR1403	Other	Method	
Al-Attas, Rabab A. M	8062		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Arnold, Paula PhD	5462		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Bengochea, Carrette	8045	31	+	+	+	+	+	+	+	+	+	+	+										+	+			LMX
Cecka, J. Michael P	774	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX
Chen, Dong-Feng P	3224		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX
Colombe, Beth W. F	3632	78	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				DR16		LMX
Daniel, Dolly	5219	30	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+		+	DR3,DR5,DR6		LMX
Du, Keming	8086	38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Dunckley, Heather	3766	78	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX
Fort, Marylise	4079		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Gebel, Howard PhD	5214	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Hahn, Amy B. PhD	910		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Hamdi, Nuha	810	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				DQ7		LMX
Hogan, Patrick	3808		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	DR3		LMX
Holdsworth, Rhonda	615		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				DPB1*04:02		LMX
Mayne, Elizabeth	8103	31	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+		+	DR3		LMX
McCluskey, James	3582		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	DQA1*05:05		LMX
Pancoska, Carol Ph	54		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Permpikul, Vejbaesy	3966	35	+	+	+	+	+	+	+	+	+			+	+					+	+					DPA1*01,DPA1*04	LMX
Pule, Ziningi	8058	39	+	+	+	+	+					+	+													DQ7	LMX
Reed, Elaine F. PhD	3753		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Sacchi, Nicoletta	8100		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
V.Brouard, M.Tonye	8048	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Vather/JHB,	4322		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					DR16,DPA1*01,DPA1*04	LMX
Vather/Pinetown,	8082		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					DR15,DR16,DPA1*01,DPA1*04	LMX

Table 32. Individual laboratory results for Serum #1236 by Luminex - class II

		**** Serum 1236 ****																					
Investigator	Ctr	% POS	DQ4	DQ8	DQ9	DR1	DR4	DR9	DQ6	DR53	DQ5	DR7	DQA1*03	DR14	DR10	DQ2	DR51	DR15	DQ7	DQA1*01	Other	Method	
Al-Attas, Rabab A. M	8062		+	+	+	+	+	+	+	+	+	+	+	+	+		+						LMX
Arnold, Paula PhD	5462		+	+	+	+	+	+	+	+	+	+	+	+									LMX
Bengochea, Carrette	8045	35	+	+	+	+	+	+	+	+	+	+				+			+				LMX
Cecka, J. Michael P	774	89	+	+	+	+	+	+	+	+	+	+				+							LMX
Chen, Dong-Feng P	3224		+	+	+	+	+	+	+	+	+	+	+	+		+							LMX
Colombe, Beth W. F	3632	85	+	+	+	+	+	+	+	+	+	+	+										LMX
Daniel, Dolly	5219	32	+	+	+	+	+	+	+	+		+										DQ3	LMX
Du, Keming	8086	33	+	+	+	+	+	+	+	+	+			+		+				+			LMX
Dunckley, Heather	3766	93	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX
Fort, Marylise	4079		+	+	+	+	+	+	+	+	+	+											LMX
Gebel, Howard PhD	5214	99	+	+	+	+	+	+	+	+	+	+	+	+									LMX
Hahn, Amy B. PhD	910		+	+	+	+	+	+	+	+	+	+	+		+								LMX
Hamdi, Nuha	810	89	+	+	+	+	+	+	+	+	+	+		+	+	+	+		+				LMX
Hogan, Patrick	3808		+	+	+	+	+	+	+	+	+	+											LMX
Holdsworth, Rhonda	615		+	+	+	+	+	+	+	+	+	+	+	+	+		+	+					LMX
Mayne, Elizabeth	8103	33	+	+	+	+	+	+	+	+	+	+	+								+	DQ3,DQA1*04	LMX
McCluskey, James	3582		+	+	+	+	+	+	+	+	+	+	+	+	+		+	+				DRB5*02:02	LMX
Pancoska, Carol Ph	54		+	+	+	+	+	+	+	+	+	+	+	+									LMX
Permpikul, Vejbaesy	3966	31	+	+	+	+	+	+	+	+	+	+	+								+		LMX
Pule, Ziningi	8058	45	+	+	+	+	+	+			+	+		+	+	+		+	+				LMX
Reed, Elaine F. PhD	3753		+	+	+	+	+	+	+	+	+	+										DRB1*14:02,DQA1*03:01	LMX
Sacchi, Nicoletta	8100		+	+	+	+	+	+	+	+	+	+		+	+	+	+		+				LMX
V.Brouard, M.Tonye	8048	89	+	+	+	+	+	+	+	+	+	+	+	+									LMX
Vather/JHB,	4322		+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		+		DP13,DP23	LMX
Vather/Pinetown,	8082		+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		+		DP23	LMX